Business
Piramal Pharma Moves to Buy Full Control of Yapan Bio
Reported by Imran Qureshi (Staff Writer) · The Hindu - Business ·

Piramal Pharma is increasing its stake in the contract development and manufacturing organisation Yapan Bio from 74 percent to 100 percent.
Acquisition Details
Discussions with Yapan shareholders are currently under way. The final terms, including the acquisition cost and effective date, are still pending finalisation. The Administrative Committee of the Piramal Pharma Board approved exercising the company's call option to buy the remaining 26 percent equity stake. Once the transaction is complete, Yapan will operate as a wholly owned subsidiary.
Company Background
Yapan is based in Hyderabad's Genome Valley. The company focuses on process development, characterisation, and Phase I and II GMP manufacturing services for vaccines and biologics. Piramal Pharma first bought a 27.78 percent stake in Yapan Bio in December 2021 for more than 101 crore rupees. In August of this year, Piramal completed another purchase of 1,46,400 equity shares from existing shareholders for around 76 crore rupees, which raised its shareholding from 33.33 percent to 74 percent.
Context
This full takeover allows Piramal to fully embed Yapan's advanced large molecule capabilities into its integrated service offering. Such moves help pharmaceutical companies expand their service portfolios in complex biological therapies and vaccines. Genome Valley in Hyderabad is a major hub for life sciences and biotechnology research in India.
More in Business
BusinessVerified — Confirmed by a second source: Google News - USA BusinessMajor
Anthropic public share offering hits $107 billion.
Reported by Vivek Joshi (Copy Editor) · Business Standard - Top Stories ·
